- Home
- ECOR vs STTK Comparison
ECOR vs STTK Comparison
Compare ECOR & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECOR
- STTK
- Stock Information
- Founded
- ECOR 2005
- STTK 2016
- Country
- ECOR United States
- STTK United States
- Employees
- ECOR N/A
- STTK N/A
- Industry
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- ECOR Health Care
- STTK Health Care
- Exchange
- ECOR Nasdaq
- STTK Nasdaq
- Market Cap
- ECOR 40.1M
- STTK 36.2M
- IPO Year
- ECOR 2018
- STTK 2020
- Fundamental
- Price
- ECOR $6.02
- STTK $0.77
- Analyst Decision
- ECOR Strong Buy
- STTK Hold
- Analyst Count
- ECOR 2
- STTK 4
- Target Price
- ECOR $25.50
- STTK $3.00
- AVG Volume (30 Days)
- ECOR 130.4K
- STTK 301.6K
- Earning Date
- ECOR 05-07-2025
- STTK 05-01-2025
- Dividend Yield
- ECOR N/A
- STTK N/A
- EPS Growth
- ECOR N/A
- STTK N/A
- EPS
- ECOR N/A
- STTK N/A
- Revenue
- ECOR $25,182,000.00
- STTK $5,721,000.00
- Revenue This Year
- ECOR $32.20
- STTK N/A
- Revenue Next Year
- ECOR $46.27
- STTK N/A
- P/E Ratio
- ECOR N/A
- STTK N/A
- Revenue Growth
- ECOR 57.09
- STTK 245.26
- 52 Week Low
- ECOR $5.02
- STTK $0.69
- 52 Week High
- ECOR $19.49
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- ECOR 33.07
- STTK 40.89
- Support Level
- ECOR $5.20
- STTK $0.85
- Resistance Level
- ECOR $6.47
- STTK $0.95
- Average True Range (ATR)
- ECOR 0.71
- STTK 0.17
- MACD
- ECOR 0.33
- STTK -0.01
- Stochastic Oscillator
- ECOR 49.26
- STTK 10.15
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.